Dapoxetine for premature ejaculation

Dapoxetin > dapoxetine sex


(2009) Treatment benefit of dapoxetine for premature

Additional information

There is no NICE guidance on premature ejaculation. A. Menarini Farmaceutica Internazionale (2013) Priligy 30 mg and 60 mg film-coated tablets summary of product characteristics [online; accessed 12 March 2014] Buvat J, Tesfaye F, Rothman M et al. (2009) Dapoxetine for the treatment of premature ejaculation: results from a randomized, double-blind, placebo-controlled phase 3 trial in 22 countries. European Association of Urology (2014) Guidelines on male sexual dysfunction [online; accessed 11 April 2014] Kaufman JM, Rosen RC, Mudumbi RV et al. ejaculation: results from a

Product Dosage Quantity + Bonus Price
Priligy Generic Dapoxetine60mg10 Pills47.63€ 45.36€
Priligy Generic Dapoxetine60mg90 + 10 Pills265.64€ 252.99€
Priligy Generic Dapoxetine60mg30 + 6 Pills106.65€ 101.57€
Levitra Soft Tabs20mg270 + 10 Pills521.78€ 496.93€
Cialis Original20mg120 + 8 Pills497.29€ 473.61€
Priligy Generic Dapoxetine60mg120 + 10 Pills341.26€ 325.01€
Kamagra Gold50 mg12 Pills47.30€ 45.05€
Priligy Generic Dapoxetine60mg180 + 10 Pills494.76€ 471.20€
Cialis Generic10mg30 + 4 Pills63.32€ 60.30€
Priligy Generic Dapoxetine60mg20 + 4 Pills77.31€ 73.63€
Cialis Generic60mg270 + 10 Pills443.96€ 422.82€
Viagra Professional100mg270 + 6 Pills456.97€ 435.21€
Levitra Generic20mg360 + 10 Pills458.44€ 436.61€
Levitra Generic60mg10 Pills47.42€ 45.16€
Priligy Generic Dapoxetine60mg60 + 8 Pills183.06€ 174.34€

placebo-controlled phase III trial.

Product details

For missing data post-baseline, the last post-baseline observation carried forward (LPOCF) method was used. In this approach, regardless of when a patient left the trial (for example, after week 1, week 6 or week 12), the last available result for that patient was carried forward and analysed as though it were the result at the study end. As stated in the summary of product characteristics, the efficacy and safety of dapoxetine in men with both premature ejaculation and erectile dysfunction treated with both dapoxetine and phosphodiesterase type 5 inhibitors (for example, sildenafil) has not been established. The summary of product characteristics states that dapoxetine should not be used in men taking phosphodiesterase type 5 inhibitors. There are limited data available on the dapoxetine tadalafil tablets safety and efficacy of dapoxetine 'on demand' for longer than 24 weeks.

Evidence review

The European Association of Urology 2014 guidelines on male sexual dysfunction recommend that pharmacological treatment options include 'on demand' dapoxetine, daily use of a longer-acting selective serotonin reuptake inhibitor (SSRI) [off-label use], daily use of clomipramine (off-label use), 'on demand' topical local anaesthetic agents (off-label use) and 'on demand' tramadol (off-label use). Because longer-acting SSRIs such as citalopram, fluoxetine or paroxetine have a longer onset of action than the shorter-acting dapoxetine they need to be taken on a daily basis and cannot be used as an 'on demand' treatment. The European Association of Urology 2014 guidelines on male sexual dysfunction states that in men for whom premature ejaculation causes few if any problems treatment should be limited to psychosexual counselling and education. The guidelines recommend that before beginning treatment, it is essential to discuss the expectations of treatment thoroughly. Various behavioural techniques have demonstrated benefit in treating premature ejaculation and are indicated for men who are uncomfortable with pharmacological therapy.

Written and reviewed by our qualified team

In lifelong premature ejaculation, the European guidelines state that behavioural techniques are not recommended for first-line treatment because they are time-intensive, require the support of a partner and can be difficult to do. The guidelines recommend that pharmacological treatment options include 'on demand' dapoxetine and daily use of a longer-acting SSRI such as citalopram, fluoxetine or paroxetine (off-label use) or daily use of clomipramine (off-label use). Dapoxetine is taken 'on demand' approximately 1 to 3 hours before anticipated sexual activity. This may reduce the incidence of SSRI-related adverse effects compared with the off-label use of once-daily longer acting SSRIs, although there are no direct RCTs to provide evidence for this. However, some men may prefer to take a daily dose which may allow more spontaneity than a planned 'on demand' treatment. (2010) Treatment of premature

Attribute Description Notes
Purpose Delays ejaculation time during intercourse Often prescribed for PE
Typical Dosage 30 mg to 60 mg Taken 1-3 hours before sex
Onset of Action Within 1-3 hours Peak effect approximately 1 hour after intake
Duration of Effect 2 to 4 hours Varies per individual
Common Side Effects Nausea, dizziness, headache Usually mild
Contraindications Use with MAO inhibitors, severe cardiac issues Consult doctor before use

ejaculation in the Asia-Pacific region:

  • Summary: a targeted on-demand treatment for premature ejaculation.
  • Requires professional diagnosis and prescription for safe use.
  • Most side effects are mild and manageable.
  • Serious risks include serotonin syndrome and syncope.
  • Improves ejaculatory control and sexual satisfaction.
  • Part of a holistic management strategy.
  • Patient education on expectations and safety is paramount.
  • Regular medical follow-up ensures optimal and safe use.

results from a phase III

Approach Considerations

Out of the 96 men who decided to start dapoxetine, only 10 men were continuing the treatment after 1 year. Dapoxetine is the only medicine licensed in the UK for the treatment of premature ejaculation, although other treatments are used off-label for this indication. The General Medical Council advice to use a licensed medicine whenever possible should be taken into consideration. The manufacturer has estimated that based on a GP-registered population of 100,000 people, 5851 men aged 18 to 64 will be affected by premature ejaculation with 1151 men severely affected (A. Menarini Farmaceutica Internazionale: personal communication January 2014).

Common side effects of Dapoxetine

The manufacturer further estimates that 25% of the men severely affected by premature ejaculation will seek treatment and 70% of those seeking treatment could be prescribed dapoxetine. The manufacturer therefore estimates that based on a GP-registered population of 100,000, 202 men aged 18 to 64 may potentially be prescribed dapoxetine over a 5-year period (A. Menarini Farmaceutica Internazionale: personal communication January 2014). The manufacturer estimated that in 2013 approximately 75% of European sales of dapoxetine were for the 30 mg strength. Dapoxetine for premature ejaculation was not considered appropriate for a NICE technology appraisal and is not currently planned into any other work programme. double-blind, parallel-group study of dapoxetine.

  • Dapoxetine is a short-acting SSRI used to treat premature ejaculation.
  • It is taken approximately 1-3 hours before sexual activity for best effects.
  • Dapoxetine helps increase control over ejaculation and delays climax.
  • Common side effects include nausea, dizziness, and headaches.
  • It is generally well-tolerated but should be used under medical supervision.
  • Combining dapoxetine with alcohol can increase side effects and reduce effectiveness.

The Journal of Sexual Medicine 7: 256–68

  • Dapoxetine helps improve sexual performance and decrease performance anxiety.
  • It is a part of a broader treatment approach for premature ejaculation.
  • Not recommended for men with a history of seizures or heart issues.
  • Dapoxetine's effects may vary depending on individual health factors.
  • Combining dapoxetine with other medications should only be done under supervision.
  • Always follow dosage instructions to ensure safety and efficacy.

McMahon CG, Althof SE, Kaufman JM et al.

How long does dapoxetine make you last in bed

For further information on contraindications, cautions and warnings please refer to the summary of product characteristics. The pooled analysis included data from 6081 men and reported results for both IELT and patient-reported outcomes such as perceived control over ejaculation. However, there are no RCTs that compare 'on demand' dapoxetine with an active comparator, such as daily use of a longer-acting SSRI (off-label use). The studies only included men aged 18 years and over who had been in a monogamous heterosexual relationship for at least 6 months and who met Diagnostic and Statistical Manual of Mental Health Disorders, 4th edition, text revision (DSM-IV-TR) criteria for premature ejaculation. In 4 of the RCTs included in the pooled analysis, participants also had to have an intravaginal ejaculatory latency time of 2 minutes or less, and this is reflected in the licensed indication.

About the authorView full bio

Only 3 of the studies included in the pooled analysis stated how frequently men were to try to attempt sexual intercourse; the other 2 included studies did not state this. The average age of men in the pooled analysis was 41 years. The efficacy and safety of dapoxetine have not been established in men aged 65 years and over. 2006) included in the pooled analysis, the method of allocation described suggests that this was concealed. However, in the other 2 RCTs (McMahon et al.

Conflict of interest

2009) it is unclear if allocation was concealed. The efficacy outcomes were reported to be based on the intention-to-treat (ITT) population, classed as all randomised participants. However, in the pooled analysis, numbers of participants for whom data were available was also presented. It is unclear if the analysis was based on the ITT population or the population for whom data were available. Discontinuation rates were high in the studies but were similar for dapoxetine and placebo (31.1% of all participants in the dapoxetine groups and 28.9% of all participants in the placebo groups).